Biopharma’s acute myeloid leukaemia treatment gains orphan drug designation

08:22 EDT 20 Aug 2018 | EPM Magazine

Clinical-stage biopharmaceutical company, ASLAN Pharmaceuticals, has been granted orphan drug designation (ODD) for its treatment for acute myeloid leukaemia (AML) — ASLAN003 — by the US Food and Drug Administration (FDA).

More From BioPortfolio on "Biopharma’s acute myeloid leukaemia treatment gains orphan drug designation"